within Pharmacolibrary.Drugs.ATC.C;

model C07AA05_1
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0006833333333333333,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.179,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0516,
    k12             = 22.1,
    k21             = 22.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C07AA05_1</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Propranolol is a non-selective beta-adrenergic receptor blocker used for the management of hypertension, angina pectoris, arrhythmias, myocardial infarction, and for the prevention of migraine headaches. It is one of the first beta-blockers developed and is widely approved for clinical use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following intravenous administration in healthy adults.</p><h4>References</h4><ol><li><p>Cenani, A, et al., &amp; Madigan, JE (2017). Pharmacokinetics and pharmacodynamics of intravenous romifidine and propranolol administered alone or in combination for equine sedation. <i>Veterinary anaesthesia and analgesia</i> 44(1) 86–97. DOI:<a href=&quot;https://doi.org/10.1111/vaa.12410&quot;>10.1111/vaa.12410</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27426730/&quot;>https://pubmed.ncbi.nlm.nih.gov/27426730</a></p></li><li><p>Routledge, PA, &amp; Shand, DG (1979). Clinical pharmacokinetics of propranolol. <i>Clinical pharmacokinetics</i> 4(2) 73–90. DOI:<a href=&quot;https://doi.org/10.2165/00003088-197904020-00001&quot;>10.2165/00003088-197904020-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/378502/&quot;>https://pubmed.ncbi.nlm.nih.gov/378502</a></p></li><li><p>Aramaki, S, et al., &amp; Koizumi, T (2000). Pharmacokinetics of propranolol and its metabolites in horses after intravenous or oral administration. <i>Biological &amp; pharmaceutical bulletin</i> 23(11) 1333–1340. DOI:<a href=&quot;https://doi.org/10.1248/bpb.23.1333&quot;>10.1248/bpb.23.1333</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11085362/&quot;>https://pubmed.ncbi.nlm.nih.gov/11085362</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C07AA05_1;
